334 related articles for article (PubMed ID: 37370736)
1. Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.
Plachouri KM; Florou V; Georgiou V; Georgiou S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370736
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
4. Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration.
Çelik U; Aydemir EH; Engin B; Oba MÇ; Yılmaz M; Meşe ŞG
J Oncol Pharm Pract; 2021 Dec; 27(8):1853-1860. PubMed ID: 33131448
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.
Khorasanchi A; Wu R; Kendra K; Verschraegen C
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358744
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
8. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
Khaddour K; Musiek A; Cornelius LA; Dehdashti F; Westervelt P; Fields R; Ansstas G
J Immunother Cancer; 2019 Dec; 7(1):338. PubMed ID: 31801591
[TBL] [Abstract][Full Text] [Related]
9. Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.
Chan SWS; Shukla R; Ramsay J; McWhirter E; Barnfield P; Juergens RA
Curr Oncol; 2023 Apr; 30(5):4527-4537. PubMed ID: 37232800
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma.
Ma VT; Haring CT; Warrier G; Swiecicki PL
Facial Plast Surg; 2020 Apr; 36(2):186-193. PubMed ID: 32413927
[TBL] [Abstract][Full Text] [Related]
11. Investigative Landscape in Advanced Non-Melanoma Skin Cancers.
Reddy P; Yao M; Patel M
Curr Treat Options Oncol; 2021 Jun; 22(7):56. PubMed ID: 34097150
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ; Djavid AR; Grimes JM; Khaleel AE; Soliman YS; Maisel-Campbell A; Garcia-Saleem TJ; Geskin LJ; Carvajal RD
Front Oncol; 2021; 11():734354. PubMed ID: 34988009
[TBL] [Abstract][Full Text] [Related]
14. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer.
Wilken R; Criscito M; Pavlick AC; Stevenson ML; Carucci JA
Facial Plast Surg; 2020 Apr; 36(2):200-210. PubMed ID: 32413929
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous malignancies in patients with Parkinson's disease at a dermato-oncological university centre in Hungary.
Tóth V; Diakoumakou SC; Kuroli E; Tóth B; Kuzmanovszki D; Szakonyi J; Lőrincz KK; Somlai B; Kárpáti S; Holló P
Front Oncol; 2023; 13():1142170. PubMed ID: 37274278
[TBL] [Abstract][Full Text] [Related]
17. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
18. Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany.
Kramb F; Doerfer C; Meiwes A; Ramakrishnan K; Eigentler T; Garbe C; Keim U; Leiter U
Acta Derm Venereol; 2022 Jan; 102():adv00637. PubMed ID: 34842930
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?
Ribero S; Stucci LS; Daniels GA; Borradori L
Curr Opin Oncol; 2017 Mar; 29(2):129-135. PubMed ID: 28151757
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Malignancies of the Head and Neck.
In GK; Thomas JS; Silk AW
Hematol Oncol Clin North Am; 2021 Oct; 35(5):991-1008. PubMed ID: 34281755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
